In the Spring 2020 edition of IAM, Christopher Loh was quoted on what the current wave of biosimilar litigation signals for the future.

According to the article, the substantial increase in patent litigation involving biosimilar drugs over the past few years has raised important new strategic and legal questions for life sciences IP practitioners. The Biologics Price Competition and Innovation Act 2009, which created a new regulatory approval pathway for biosimilars in the United States, introduced a distinctive IP litigation framework. Centered on the multi-step exchange of information known as the ‘patent dance’, this framework also differs from that which governs generic small-molecule drug litigation.

Patent dance strategies seem to correlate to the number and type of IP rights protecting the relevant reference product. “The Biologics Price Competition and Innovation Act lawsuits we have seen so far can be divided into two categories,” comments Loh.

“The first category includes cases involving mature biologic products, such as filgrastim and epoetin, whose basic composition of matter patents and regulatory exclusivities had expired before the litigation started,” he explains. “These cases have tended to involve manufacturing patents filed later on in the product’s lifecycle. Because there was no regulatory exclusivity when the biosimilars were approved, the biosimilar producers took a relatively aggressive approach in interpreting the act’s patent dance provisions.”

The second category that Loh identifies is that where the reference biologic had a lengthy period of regulatory exclusivity remaining after the passage of the act. “In these cases, exclusivity incentivised both sides to participate in the patent dance. This allowed the biosimilar producers to gain some intelligence about the innovators’ patent portfolios, without any downside in terms of delay to launch date.”

Despite the flexibility that biosimilar producers have, participation in the dance is only likely to grow in years to come, according to Loh.


    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates